Concepts (74)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 11 | 2022 | 1721 | 0.990 |
Why?
|
| Watchful Waiting | 5 | 2022 | 60 | 0.940 |
Why?
|
| Testosterone | 1 | 2016 | 271 | 0.500 |
Why?
|
| Quality of Life | 4 | 2022 | 1585 | 0.450 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 2 | 2018 | 52 | 0.310 |
Why?
|
| Anxiety | 2 | 2019 | 287 | 0.240 |
Why?
|
| Mindfulness | 1 | 2022 | 9 | 0.220 |
Why?
|
| Self-Management | 1 | 2022 | 29 | 0.200 |
Why?
|
| Germ-Line Mutation | 3 | 2018 | 329 | 0.190 |
Why?
|
| Multifactorial Inheritance | 1 | 2021 | 159 | 0.180 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2018 | 23 | 0.160 |
Why?
|
| Genes, BRCA2 | 1 | 2018 | 160 | 0.150 |
Why?
|
| Genes, BRCA1 | 1 | 2018 | 192 | 0.150 |
Why?
|
| Sexuality | 1 | 2016 | 40 | 0.140 |
Why?
|
| BRCA2 Protein | 1 | 2016 | 158 | 0.130 |
Why?
|
| Biopsy, Needle | 2 | 2014 | 235 | 0.130 |
Why?
|
| BRCA1 Protein | 1 | 2016 | 200 | 0.130 |
Why?
|
| Aged | 9 | 2021 | 18423 | 0.130 |
Why?
|
| Personality | 1 | 2016 | 134 | 0.130 |
Why?
|
| Prostate-Specific Antigen | 2 | 2014 | 353 | 0.120 |
Why?
|
| Male | 12 | 2022 | 40988 | 0.120 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 455 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2021 | 2357 | 0.110 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2012 | 59 | 0.110 |
Why?
|
| Erectile Dysfunction | 1 | 2012 | 74 | 0.100 |
Why?
|
| Physicians, Primary Care | 1 | 2013 | 104 | 0.100 |
Why?
|
| Neoplasm Grading | 3 | 2018 | 357 | 0.100 |
Why?
|
| Decision Making | 1 | 2016 | 642 | 0.090 |
Why?
|
| Prostate | 1 | 2014 | 378 | 0.090 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2022 | 166 | 0.090 |
Why?
|
| Middle Aged | 9 | 2021 | 25040 | 0.090 |
Why?
|
| Mass Screening | 1 | 2013 | 619 | 0.080 |
Why?
|
| Humans | 13 | 2022 | 86678 | 0.080 |
Why?
|
| Benzenesulfonates | 1 | 2007 | 66 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 1037 | 0.070 |
Why?
|
| Pyrroles | 1 | 2007 | 184 | 0.070 |
Why?
|
| Retrospective Studies | 2 | 2016 | 8496 | 0.070 |
Why?
|
| Indoles | 1 | 2007 | 318 | 0.070 |
Why?
|
| Pyridines | 1 | 2007 | 310 | 0.060 |
Why?
|
| Prognosis | 3 | 2018 | 3680 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2021 | 2768 | 0.060 |
Why?
|
| Spouses | 1 | 2022 | 33 | 0.060 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2007 | 426 | 0.050 |
Why?
|
| Kidney Neoplasms | 1 | 2007 | 621 | 0.050 |
Why?
|
| Stress, Psychological | 1 | 2022 | 313 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2022 | 840 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2019 | 111 | 0.040 |
Why?
|
| Genetic Carrier Screening | 1 | 2018 | 60 | 0.040 |
Why?
|
| Self Report | 1 | 2019 | 288 | 0.040 |
Why?
|
| Risk Factors | 2 | 2021 | 5420 | 0.040 |
Why?
|
| Heterozygote | 1 | 2018 | 365 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 526 | 0.040 |
Why?
|
| Time Factors | 2 | 2016 | 5214 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 84 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2007 | 2360 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 861 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 860 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 853 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2013 | 90 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 1538 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1807 | 0.030 |
Why?
|
| Age Factors | 1 | 2016 | 1852 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2013 | 224 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 2504 | 0.020 |
Why?
|
| Adult | 3 | 2019 | 25659 | 0.020 |
Why?
|
| Disease Progression | 1 | 2014 | 1532 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2013 | 584 | 0.020 |
Why?
|
| Leiomyomatosis | 1 | 2007 | 12 | 0.020 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2007 | 17 | 0.020 |
Why?
|
| Niacinamide | 1 | 2007 | 116 | 0.020 |
Why?
|
| Phenylurea Compounds | 1 | 2007 | 114 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 3642 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2014 | 4214 | 0.020 |
Why?
|
| United States | 1 | 2013 | 6681 | 0.010 |
Why?
|